Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Joseph C. Glorioso
University of Pittsburgh at Pittsburgh, Department: Neurosurgery
Should you be removed from our database? Contact us at [email protected]. Read more below.
Oncorus
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
Dr. Glorioso's conflict arises due to his interest as an inventor of intellectual property being evaluated/developed in bench research funded by this grant, which the University of Pittsburgh licensed to Oncorus. Dr. Glorioso also consults for Oncorus and has an ownership interest in the company.
Enhanced GBM Therapy Using a New Class of HSV Oncolytic Vector
Glioblastoma multiforme (GBM) is a deadly brain tumor without effective therapy. Oncolytic herpes simplex viral vectors (OVs) provide an attractive treatment alternative however clinical trials have thus far been disappointing. We propose to create a new oHSV that is not compromised for growth through attenuating mutagenesis but rather our vector will be essentially a wild type virus in order to ensure the most robust virus replication and lytic activity in tumor cells. We will ensure vector safety and tumor specificity b engineering this new oHSV to utilize tumor related receptors and limit growth in normal tissue through cellular microRNA control of vector growth. We anticipate that this new vector design will be far more effective in tumor treatment and can be developed for patient trials.
Filed on June 21, 2017.
Tell us what you know about Joseph C. Glorioso's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Joseph C. Glorioso filed other conflict of interest disclosures with the NIH:
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Joseph Glorioso | University of Pittsburgh at Pittsburgh | Conflict of Interest | Oncorus, Inc. | $100,000 - $149,999 |
| Joseph C. Glorioso | University of Pittsburgh at Pittsburgh | Conflict of Interest | Oncorus | $100,000 - $149,999 |
| Joseph C. Glorioso | University of Pittsburgh at Pittsburgh | Conflict of Interest | Oncorus | $5,000 - $9,999 |
| Joseph Glorioso | University of Pittsburgh at Pittsburgh | Conflict of Interest | Oncorus, Inc. | Value cannot be readily determined |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.